Loading patent…
AssigneesInstitut Curie, Mnemo Therapeutics, Institut National de la Sante et de la Recherche Medicale
InventorsSebastian Amigorena, Marianne Burbage, Alexandre Houy, Marc-Henri Stern, Joshua Waterfall, Benjamin Sadacca, Antonela Merlotti Ippolito, Yago Arribas De Sandoval
Estimating the term…
The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: —a step of identifying, among mRNA sequences from cancer cells of a subject, a fusion transcript sequence comprising a transposable element (TE) sequence and an exonic sequence, and including an open reading frame (ORF), and—a step of selecting a tumor neoantigenic peptide of at least 8 amino acids, encoded by a part of said ORF of the fusion transcript sequence, wherein said ORF overlaps the junction between the TE and the exonic sequence, is pure TE and/or is non-canonical, and wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.
A method of treating cancer, inhibiting cancer cell proliferation or providing cancer vaccination therapy in a subject, the method comprising administering to the subject in need thereof a composition comprising a tumor neoantigenic peptide comprising at least 8 amino acids, or a nucleic acid encoding the tumor neoantigenic peptide, wherein the neoantigenic peptide is encoded by a part of an open reading frame (ORF) from a fusion transcript comprising a transposable element (TE) sequence and an exonic sequence, and wherein the ORF overlaps the junction between the TE and the exonic sequence, is pure TE or is non-canonical.
Dependencies are inferred from the claim text.